Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Ms. Marianne L. Romeo

Head of Global Transactions & Risk Management

Dr. Mayukh  Sukhatme M.D.

President, Chief Investment Officer & Director

Dr. Eric  Venker M.D., Pharm.D.

President & Chief Operating Officer

Ms. Kelly  Graff

Head of People

Mr. Jo  Chen

General Counsel

Mr. Alex  Gasner

Executive Vice President of Roivant Health

Mr. Matthew  Gline

Chief Executive Officer & Director

Mr. Richard  Pulik

Chief Financial Officer

Ms. Rakhi  Kumar

Chief Accounting Officer

Dr. Huafeng  Xu Ph.D.

Chief Technology Officer

Biotechnologie

Roivant Sciences Ltd.

Roivant Sciences Ltd. Management-Struktur

Informationen zum Management